JP2024540863A5 - - Google Patents
Info
- Publication number
- JP2024540863A5 JP2024540863A5 JP2024522065A JP2024522065A JP2024540863A5 JP 2024540863 A5 JP2024540863 A5 JP 2024540863A5 JP 2024522065 A JP2024522065 A JP 2024522065A JP 2024522065 A JP2024522065 A JP 2024522065A JP 2024540863 A5 JP2024540863 A5 JP 2024540863A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- taa
- multispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021123374 | 2021-10-12 | ||
| CNPCT/CN2021/123374 | 2021-10-12 | ||
| CN2022104995 | 2022-07-11 | ||
| CNPCT/CN2022/104995 | 2022-07-11 | ||
| PCT/CN2022/124961 WO2023061417A1 (en) | 2021-10-12 | 2022-10-12 | Cd3-targeting t-cell engagers with improved therapeutic index |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540863A JP2024540863A (ja) | 2024-11-06 |
| JP2024540863A5 true JP2024540863A5 (https=) | 2025-10-22 |
Family
ID=85987305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522065A Pending JP2024540863A (ja) | 2021-10-12 | 2022-10-12 | 改善された治療指数を有するｃｄ３標的化ｔ細胞エンゲージャー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240417469A1 (https=) |
| EP (1) | EP4415825A4 (https=) |
| JP (1) | JP2024540863A (https=) |
| CN (1) | CN118556083A (https=) |
| WO (1) | WO2023061417A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202532431A (zh) * | 2023-09-21 | 2025-08-16 | 大陸商樂普創一生物科技（上海）有限公司 | 多特異性抗體及其用途 |
| WO2025103425A1 (en) * | 2023-11-15 | 2025-05-22 | Concept To Medicine Biotech Co., Ltd. | Multispecific antibodies and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201909160WA (en) * | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| KR20260046525A (ko) * | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| EP3827019A1 (en) * | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| US12509524B2 (en) * | 2018-09-28 | 2025-12-30 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
| CN113166261A (zh) * | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| JP2022504802A (ja) * | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | ５ｔ４シングルドメイン抗体およびその治療組成物 |
| CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| US12060434B2 (en) * | 2020-02-25 | 2024-08-13 | Gensun Biopharma Inc. | Trispecific T cell engagers |
-
2022
- 2022-10-12 US US18/700,213 patent/US20240417469A1/en active Pending
- 2022-10-12 EP EP22880353.2A patent/EP4415825A4/en active Pending
- 2022-10-12 CN CN202280082274.2A patent/CN118556083A/zh active Pending
- 2022-10-12 WO PCT/CN2022/124961 patent/WO2023061417A1/en not_active Ceased
- 2022-10-12 JP JP2024522065A patent/JP2024540863A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7438958B2 (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| Niquille et al. | Biparatopic antibodies: therapeutic applications and prospects | |
| Zhou et al. | Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2022545660A5 (https=) | ||
| JP2023506184A5 (https=) | ||
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| Pekar et al. | Biophysical and biochemical characterization of a VHH-based IgG-like bi-and trispecific antibody platform | |
| JP2013527761A5 (https=) | ||
| KR20170085531A (ko) | 항-cldn 키메라 항원 수용체 및 사용 방법 | |
| JP2023537002A5 (https=) | ||
| JP2023524102A5 (https=) | ||
| CN114466868A (zh) | 一种双特异性融合蛋白及其应用 | |
| JP2024515560A5 (https=) | ||
| JP2024540863A5 (https=) | ||
| CN110072892A (zh) | Mg7，高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 | |
| JP2024001073A5 (https=) | ||
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| JP2023502990A5 (https=) | ||
| Sugiyama et al. | A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity | |
| EP4054649A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| CN115894702A (zh) | 一种b7h3/pdl1双特异性抗体及其药物组合物及应用 | |
| WO2025067496A1 (zh) | 靶向baff-r的全人源抗体、car-t细胞及其应用 | |
| US20260055201A1 (en) | Bispecific antibody and use thereof | |
| US20260092116A1 (en) | B7h3/pdl1 bispecific antibody, and pharmaceutical composition comprising same and use thereof |